Latest Forum Topics /
IX Biopharma
Last:0.34
-0.005
|
 Post Reply
|
|
iX Biopharma
|
|||||
|
SmallSmall
Supreme |
27-Apr-2020 09:46
|
||||
|
x 0
x 0 Alert Admin |
Last chance for such cheap pricing ..... :)
|
||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
27-Apr-2020 09:45
|
||||
|
x 0
x 0 Alert Admin |
This is a pretty decent company with a few very interesting patents.... | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
SmallSmall
Supreme |
27-Apr-2020 09:23
|
||||
|
x 0
x 0 Alert Admin |
|
||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
27-Apr-2020 09:21
|
||||
|
x 0
x 0 Alert Admin |
|
||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
27-Apr-2020 09:13
|
||||
|
x 0
x 0 Alert Admin |
Yiling estimates the first five years of sales in China for Wafesil& trade to be around RMB 700 to 800 million
|
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
SmallSmall
Supreme |
27-Apr-2020 09:10
|
||||
|
x 0
x 0 Alert Admin |
Chiong ah ! Viagra play in big China market | ||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
27-Apr-2020 09:05
|
||||
|
x 0
x 0 Alert Admin |
This is going to be a ' Hard" buy. Next big medical stock play. NEWS RELEASE Licensing, supply and distribution of Wafesil&trade , sublingual sildenafil wafer, in China Yiling Pharmaceutical Ltd. granted an exclusive licence to register and distribute Wafesil&trade , for treatment of male erectile dysfunction, in China The agreement marks iX Biopharma&rsquo s entry into the China pharmaceutical market Singapore, 27 April 2020 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo ) is pleased to announce that it has entered into a licensing agreement with Yiling Pharmaceutical Ltd. (&ldquo Yiling&rdquo ) for the licensing, supply and distribution of Wafesil&trade , a sublingual sildenafil wafer for the treatment of male erectile dysfunction, in China (the &ldquo Wafesil China Agreement&rdquo ). Under the Wafesil China Agreement, Yiling will be granted an exclusive license to market and distribute Wafesil&trade in China after it obtains marketing authorisation in the name of iX Biopharma in China. iX Biopharma will manufacture and supply Wafesil&trade to Yiling at a supply price agreed between the parties. The initial term of the agreement is 10 years. Yiling will pay to iX Biopharma an upfront and certain milestone payments prior to the commercialisation of Wafesil&trade . The milestone payments will be made upon the completion of bioequivalence studies and on the first commercial supply of wafers by iX Biopharma to Yiling. In addition, Yiling has agreed to fund any bioequivalence studies and regulatory submissions necessary for the registration of the product in China. By partnering with Yiling, iX Biopharma will be able to access the market through Yiling&rsquo s sales and distribution network covering 100,000 medical and health institutions and over 300,000 pharmacies in China. Due to its novel and superior dosage form, Yiling estimates the first five years of sales in China for Wafesil&trade to be around RMB 700 to 800 million. Wafesil&trade is a new dose form of sildenafil, formulated using iX Biopharma&rsquo s patented sublingual drug delivery technology, WaferiX® . It is a registered pharmaceutical medicine in Australia and an application has been made to the European Medicines Agency for marketing authorisation in Europe. Mr Zhao Shaohua, President of Yiling Pharmaceutical Ltd said: &ldquo There is a significant and growing market for sildenafil in China. We see huge potential in Wafesil&trade , a quality drug imported from Australia. This is because Wafesil&trade is patented with a novel sublingual delivery, and has the potential for better absorption and faster onset of therapeutic action.&rdquo Ms Eva Tan, Director of Corporate and Commercial Strategy of iX Biopharma said: &ldquo We are delighted that in Yiling, we have a strong partner for our inaugural entry into the China pharmaceutical drug market. We have confidence in Yiling&rsquo s regulatory expertise to successfully register Wafesil&trade in China, after which we will be able to leverage on their established sales distribution network covering hospitals and pharmacies across all of China. Like Yiling, we are excited about the sales potential of Wafesil&trade in the Chinese market due to its novel, superior dosage form achieved using the WaferiX delivery technology.&rdquo Wafesil&trade is the first drug of iX Biopharma&rsquo s drug pipeline to be out-licensed. In addition to Wafesil&trade , iX Biopharma has a rich pipeline of other drugs formulated with the WaferiX® drug delivery platform technology that have the potential to be partnered for global markets. |
||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
10-Dec-2019 17:40
|
||||
|
x 0
x 0 Alert Admin |
NEWS RELEASE Singapore, 10 December 2019 &ndash Specialty pharmaceutical company iX Biopharma Ltd (SGX:42C) (&ldquo iX Biopharma&rdquo or, &ldquo the Company&rdquo ) is pleased to announce that it has successfully concluded an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding Wafermine, a sublingual ketamine wafer for the treatment of acute moderate to severe pain. During the meeting, the Company and the FDA reached agreement on key aspects of the pivotal Phase 3 clinical trial program to support approval of Wafermine for the indication of acute moderate to severe pain. The Phase 3 program consists of two randomised, double blind, placebo-controlled studies, one in an orthopaedic pain model (bunionectomy) and one in a soft-tissue pain model (abdominoplasty). Both of these post-operative pain models were successfully evaluated in the recent Phase 2b clinical study. The primary efficacy measure for both studies will be SPID12, which is the summed pain intensity difference over 12 hours. The summed pain intensity difference over 24 hours (SPID24) and 48 hours (SPID48) will be evaluated as secondary endpoints. Dr. Janakan Krishnarajah, Chief Medical Officer of iX Biopharma said: " We are very pleased with the positive outcome of our meeting with the FDA and this is a major milestone for the iX Group. We appreciate the valuable guidance the FDA has provided and look forward to continuing a constructive relationship as we advance our Phase 3 registration program. We remain focused on bringing Wafermine to market as a new and differentiated nonopioid analgesic for patients and caregivers seeking alternatives to conventional opioids.&rdquo The Phase 3 studies will be using the same post-operative pain models that were successfully evaluated in the recent Phase 2b clinical study. Accordingly, the Company is highly confident that the excellent results from this study can be replicated in the final pivotal studies. More importantly, confirmation of the EOP2 meeting with the FDA gives clarity to the Wafermine development program, especially costs and timeline. Further, it positions the Company well to continue licensing discussions with potential licensees. | ||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
SmallSmall
Supreme |
06-Dec-2019 09:22
|
||||
|
x 0
x 0 Alert Admin |
Can sell world wide. How big is the market? Anyone?
|
||||
| Useful To Me Not Useful To Me | |||||
|
SmallSmall
Supreme |
06-Dec-2019 09:17
|
||||
|
x 0
x 0 Alert Admin |
IX BIOPHARMA: Awarded Aussie medicinal cannabis manufacture licensehttps://www.nextinsight.net/story-archive-mainmenu-60/942-2019/13225-ix-biopharma-awarded-aussie-cannabis-manufacture-license |
||||
| Useful To Me Not Useful To Me | |||||
|
Bladeonline
Member |
09-Feb-2018 10:04
|
||||
|
x 0
x 0 Alert Admin |
IX BIOPHARMA SECURES CHINA PATENT FOR WAFERIX DRUG DELIVERY TECHNOLOGY Intellectual property rights now secured in key Asian markets First out-licensing agreement for WaferiX entered into with Bod Australia Singapore, 8 February 2018 ? iX Biopharma Ltd. (?iX Biopharma? or, together with its subsidiaries, ?the Group?) is pleased to announce that it has been granted a patent for its WaferiX drug delivery technology by the People?s Republic of China (Patent No. ZL 2013800602813). The patent, which expires on 11 October 2033, allows iX Biopharma to exclusively use and obtain protection for its WaferiX drug delivery technology in China. WaferiX is a fast-dissolving, proprietary wafer formulation that allows pharmacologically active compounds, such as ketamine and sildenafil, to be administered sublingually (i.e., placed under the tongue) and delivered safely, conveniently and rapidly into the blood stream. The technology offers a non-invasive, pain-free alternative to traditional routes of drug administration such as intravenous drips and injections. Key advantages of WaferiX include the reduction of the effect of first-pass metabolism, rapid onset of action, better side effect profile, easy administration, improved patient compliance and a better storage profile. The Group leverages WaferiX to develop innovative pharmaceutical and nutraceutical products, | ||||
| Useful To Me Not Useful To Me | |||||
|
waters
Senior |
21-Sep-2016 15:43
|
||||
|
x 0
x 0 Alert Admin |
iX Biopharma&rsquo s PheoniX rises to Viagra challenge, but will its share price stay up?By:
Michelle Teo
 SINGAPORE (Sept 16): News that iX Biopharma&rsquo s drug to treat male erectile dysfunction is close to appearing on pharmacy shelves has got the market excited. Shares in the Catalist company rose nearly 8% in trading on Sept 14, a day after it announced that its sublingual wafer drug, PheoniX, has generated positive results in a bioequivalence study comparing it with the market leader, Viagra. But even as iX Biopharma&rsquo s PheoniX rises to the challenge against the famous little blue pill, it&rsquo s hard to say if it can sustain the swell in its share price. (See iX Biopharma&rsquo s male erectile dysfunction drug stands up to the test) The stock had been limping along for most of the past year at the current price, the counter is still 40% off its market debut. To be sure, iX Biopharma&rsquo s chairman and CEO Eddy Lee maintains no hard feelings about poor market sentiment for the company&rsquo s stock. What will it take to revive investor sentiment? With the latest development, and more in the pipeline, can iX Biopharma&rsquo s share price stay up? Find out more in this week' s The Edge Singapore (week of Sept 19), now available at newsstands. |
||||
| Useful To Me Not Useful To Me | |||||
|
|
|||||
|
mepkoh
Elite |
19-Sep-2016 12:03
|
||||
|
x 0
x 0 Alert Admin |
yes..but with a power product that you will want now or later...
|
||||
| Useful To Me Not Useful To Me | |||||
|
Lepin888
Veteran |
19-Sep-2016 11:41
|
||||
|
x 0
x 0 Alert Admin |
This co has no rocket science product. It only has an improved mode of delivery ie under tongue for certain drugs like pain killer and viagra type. It has.no patented killer product and so use generics. So it is not going to earn huge profits hence listing here and not in nasdaq.
I recalled the last japanese co that has this technology went under after doing RTO on eng wah cinema. So investors here are not that dumbed and do some homework and thinking. |
||||
| Useful To Me Not Useful To Me | |||||
|
novena_33
Veteran |
19-Sep-2016 09:57
|
||||
|
x 0
x 0 Alert Admin |
i agreed to what u mentioned... some time i wonder why they listed in here... should go and list in USA ...let the big fish see them....and get buy over... the share price is really miserable ...
|
||||
| Useful To Me Not Useful To Me | |||||
|
n3wbie
Elite |
18-Sep-2016 18:34
|
||||
|
x 0
x 0 Alert Admin |
the biggest issue for such counters is that it is not well appreciated by local investment community..no real appetite. kinda a make or break, if they pass all trials/get FDA approval and goes into commercialisation, will be a multi-bagger, but if not, will continue to be loss making. other options include a buy-out by global players if they see the potential. |
||||
| Useful To Me Not Useful To Me | |||||
|
guiren
Veteran |
18-Sep-2016 15:21
|
||||
|
x 0
x 0 Alert Admin |
" but today jumped3.5 cts..." ,, if you try their new product, long 3.5 inches ,,
|
||||
| Useful To Me Not Useful To Me | |||||
|
mepkoh
Elite |
17-Sep-2016 08:32
|
||||
|
x 0
x 0 Alert Admin |
yeah..hard... but today jumped3.5 cts...so hard to go up..n tada..u have it.. its a standing ovation..
|
||||
| Useful To Me Not Useful To Me | |||||
|
sheerluck
Supreme |
16-Sep-2016 18:10
Yells: "Work for your money first then let your money work for you" |
||||
|
x 0
x 0 Alert Admin |
Must be " hard" to go up.
|
||||
| Useful To Me Not Useful To Me | |||||
|
mepkoh
Elite |
16-Sep-2016 17:02
|
||||
|
x 0
x 0 Alert Admin |
last done 31.. awesome hard
|
||||
| Useful To Me Not Useful To Me | |||||